Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient

American Journal of Health-System Pharmacy

Volumn 67, Issue 15, 2010, Pages 1254-1259

  Patel, Mitesh K ^a   Brunetti, Luigi ^b  

^a GRANT MEDICAL CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Antiparkinson agents; Antipsychotic agents; Aripiprazole; Bromocriptine; Clozapine; Neuroleptic malignant syndrome; Paliperidone; Schizophrenia; Toxicity

Indexed keywords

ARIPIPRAZOLE; BROMOCRIPTINE MESILATE; CLOZAPINE; PALIPERIDONE; 9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MENTAL HEALTH; NEUROLEPTIC MALIGNANT SYNDROME; OLIGURIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCHIZOPHRENIA; URINE RETENTION;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; ISOXAZOLES; NEUROLEPTIC MALIGNANT SYNDROME; PIPERAZINES; PYRIMIDINES; QUINOLONES; SCHIZOPHRENIA;

EID: 78349285184     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090243     Document Type: Article

References (37)

1. Delay J, Pichot P, Lemperiere T et al. [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses.] Ann Med Psychol. 1960; 118:145-52. In French.
2. Pelonero AL, Levenson, JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 1998; 49:1163-72. (Pubitemid 28414680)
3. Caroff SN. The neuroleptic malignant syndrome. Med Clin N Am. 1993; 77:185-202.
4. Caroff SN, Mann SC, Campbell C. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann. 2000; 5:314-21.
5. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin. 2004; 22:389-411. (Pubitemid 38388555)
6. Duggal HS, Kithas J. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine. Am J Psychiatry. 2005; 162:397-8. Letter.
7. Velamoor VR, Norman RM, Caroff SN et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994; 182:168-73. (Pubitemid 24137670)
8. Connelly MA, Fowler EK. Neuroleptic malignant syndrome. J Am Board Fam Pract. 1992; 5:327-31.
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Publishing; 2000:795-8.
10. Picard LS, Lindsay S, Strawn JR et al. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy. 2008; 28:530-5. (Pubitemid 351466464)
11. Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res. 2005; 135:249-56. (Pubitemid 40984616)
12. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatry Q. 2001; 72:325-36. (Pubitemid 33743589)
13. McEvoy GK, ed. AHFS drug information, 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2008, 2446-8.
14. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical review. CMAJ. 2005; 172:1703-11. (Pubitemid 40896865)
15. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1: "Goldilocks" actions at dopamine receptors. J Clin Psychiatry. 2001; 62:841-2.
16. Chakraborty N, Johnson T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol. 2004; 19:351-3. (Pubitemid 39506991)
17. Spalding S, Alessi NE, Radwan K. Aripiprazole and atypical neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry. 2004; 43:1457-8. Letter.
18. Srephichit S, Sanchez R, Bourgeois JA. Neuroleptic malignant syndrome and aripiprazole in an antipsychotic-naïve patient. J Clin Psychopharmacol. 2006; 26:94-5. Letter.
19. Ali S, Pearlman RL, Upadhyay A et al. Neuroleptic malignant syndrome with aripiprazole and lithium: a case report. J Clin Psychopharmacol. 2006; 26:434-6. (Pubitemid 44187651)
20. Rodriguez OP, Dowell MS. A case report of neuroleptic malignant syndrome without fever in a patient given aripiprazole. J Okla State Med Assoc. 2006; 99:435-8.
21. Kang SG, Lee HJ, Lee MS et al. Atypical neuroleptic malignant syndrome associated with aripiprazole. J Clin Psychopharmacol. 2006; 26:534. Letter.
22. Hamerman S, Lam C, Caroff SN. Neuroleptic malignant syndrome and aripiprazole. J Am Acad Child Adolesc Psychiatry. 2006; 45:639-41.
23. Caraccio T, Moghaddam T, Flori J et al. Neuroleptic malignant syndrome (NMS) induced by aripiprazole (ARP). Clin Toxicol. 2006; 44:708. Abstract.
24. Evicmen H, Alici-Evicmen Y, Basil B. Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis. J Psychiatr Pract. 2007; 13:117-9.
25. Brunelle L, Guigueno S, Gouin P et al. Aripiprazole and neuroleptic malignant syndrome. J Clin Psychopharmacol. 2007; 27:212-4.
26. Molina D, Tingle LE, Lu X. Aripiprazole as the causative agent of neuroleptic malignant syndrome: a case report. Prim Care Companion J Clin Psychiatry. 2007; 9:148-50. (Pubitemid 46607471)
27. Palakurthi HB, Parvin MM, Kaplan S. Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient. Clin Neuropharmacol. 2007; 30:47-51. (Pubitemid 46204318)
28. Marshall PB, Mellman TA, Nguyen SX. Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine. Am J Psychiatry. 2008; 165:1488-9. Letter.
29. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 31:239-45. (Pubitemid 12149145)
30. Strawn JR. Aripiprazole and the neuroleptic malignant syndrome. Schizophr Res. 2006; 85:298-9. Letter.
31. Fink M. Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry. 1996; 39:1-4. (Pubitemid 26022677)
32. Keck PE, McElroy SL, Pope HG. Neuroleptic malignant syndrome. Curr Opin Psychiatry. 1991; 4:34-7.
33. Sachdev P, Kruk J, Kneebone M et al. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol. 1995; 15:365-71.
34. Duggal HS. Possible neuroleptic malignant syndrome associated with paliperidone. J Neuropsychiatry Clin Neurosci. 2007; 19:477-8. Letter.
35. Ananth J, Aduri K, Parameswaram S et al. Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment. Acta Neurologica. 2004; 16:219-28. (Pubitemid 39663123)
36. Kawanishi C, Shimoda Y, Fuzimaki J et al. Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. J Neurol Sci. 1998; 160:102-4. (Pubitemid 28473895)
37. Invega package insert. Titusville, NJ: Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2008 Dec.